

REFERENCES

1. Ahn S, Lee YS, Lim KS, Lee JL: Emergency department cancer unit and management of oncologic emergencies: experience in Asian Medical Center. *Support Care Cancer* 20: 2205, 2012. [PMID: 22555446]
2. Sadik M, Ozlem K, Huseyin M, Ayberk BA, Ahmet S, Ozgur O: Attributes of cancer patients admitted to the emergency department in one year. *World J Emerg Med* 5: 85, 2014. [PMID: 25215154]
3. Delgado-Guay MO, Kim YJ, Shin SH, et al: Avoidable and unavoidable visits to the Emergency Department among patients with advanced cancer receiving outpatient palliative care. *J Pain Symptom Manage* 49: 497, 2015. [PMID: 25131891]
4. Lewis MA, Hendrickson AW, Moynihan TJ: Oncologic emergencies: pathophysiology, presentation, diagnosis, and treatment. *CA Cancer J Clin* 61: 287, 2011. [Epub ahead of print] [PMID: 21858793]
5. McCurdy MT, Shanholtz CB: Oncologic emergencies. *Crit Care Med* 40: 2212, 2012. [PMID: 22584756]
6. Khan UA, Shanholtz CB, McCurdy MT: Oncologic mechanical emergencies. *Emerg Med Clin North Am* 32: 495, 2014. [PMID: 25060246]
7. Wagner J, Arora S: Oncologic metabolic emergencies. *Emerg Med Clin North Am* 32: 509, 2014. [PMID: 25060247]
8. Gaisser HA, Burns J: The compromised airway: tumors, strictures, and tracheomalacia. *Surg Clin North Am* 90: 1065, 2010. [PMID: 20955884]
9. Theodore PR: Emergent management of malignancy-related acute airway obstruction. *Emerg Med Clin North Am* 27: 231, 2009. [PMID: 19447308]
10. Hashemian SM, Fallahian F: The use of heliox in critical care. *Int J Crit Illn Inj Sci* 4: 138, 2014. [PMID: 25024941]
11. Ost DE, Ernst A, Grosu HB, et al: Therapeutic bronchoscopy for malignant central airway obstruction: success rates and impact on dyspnea and quality of life. *Chest* October 30, 2014. [Epub ahead of print] [PMID: 25358019]
12. Mahmood K, Wahidi MM: Ablative therapies for central airway obstruction. *Semin Respir Crit Care Med* 35: 681, 2014. [PMID: 25463159]
13. Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. *Clin Cancer Res* 12: 6243s, 2006. [PMID: 17062708]
14. Wilkinson AN, Viola R, Brundage MD: Managing skeletal related events resulting from bone metastases. *BMJ* 337: a2041, 2008. [PMID: 18981017]
15. Penas-Prado M, Loghin ME: Spinal cord compression in cancer patients: review of diagnosis and treatment. *Curr Oncol Rep* 10: 78, 2008. [PMID: 18366964]
16. Lutz ST, Jones J, Chow E: Role of radiation therapy in palliative care of the patient with cancer. *J Clin Oncol* 32: 2913, 2014. [PMID: 25113773]
17. Wilson LD, Detterbeck FC, Yahalom J: Clinical practice. Superior vena cava syndrome with malignant causes. *N Engl J Med* 356: 1862, 2007. [Erratum in: *N Engl J Med* 358: 1083, 2008.] [PMID: 17476012]
18. Lepper PM, Ott SR, Hoppe H, et al: Superior vena cava syndrome in thoracic malignancies. *Respir Care* 56: 653, 2011. [PMID: 21276318]
19. Akl EA, Vasireddi SR, Gunukula S, et al: Anticoagulation for patients with cancer and central venous catheters. *Cochrane Database Syst Rev* 2: CD006468, 2011. [PMID: 21328283]
20. Lumachi F, Brunello A, Roma A, Bassi U: Cancer-induced hypercalcemia. *Anticancer Res* 29: 1551, 2009. [PMID: 19443365]
21. Rosner MH, Dalkin AC: Electrolyte disorders associated with cancer. *Adv Chronic Kidney Dis* 21: 7, 2014. [PMID: 24359982]
22. Charmandari E, Nicolaides NC, Chrousos GP: Adrenal insufficiency. *Lancet* 383: 2152, 2014. [PMID: 24503135]
23. Wilson FP, Berns JS: Tumor lysis syndrome: new challenges and recent advances. *Adv Chronic Kidney Dis* 21: 18, 2014. [PMID: 24359983]
24. Sutton SH: Infections associated with solid malignancies. *Cancer Treat Res* 161: 371, 2014. [PMID: 24706232]
25. White L, Ybarra M: Neutropenic fever. *Emerg Med Clin North Am* 32: 549, 2014. [PMID: 25060249]
26. Freifeld AG, Bow EJ, Sepkowitz KA, et al: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis* 52: 427, 2011. [PMID: 21205990]
27. Flowers CR, Seidenfeld J, Bow EJ, et al: Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 31: 794, 2013. [PMID: 23319691]
28. Alp S, Akova M: Management of febrile neutropenia in the era of bacterial resistance. *Ther Adv Infect Dis* 1: 37, 2013. [PMID: 25165543]
29. Klastersky J, Paesmans M, Rubenstein EB, et al: The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. *J Clin Oncol* 18: 3038, 2000. [PMID: 10944139]
30. Klastersky J, Paesmans M: The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. *Support Care Cancer* 21: 1487, 2013. [PMID: 23443617]
31. Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela-Echaburu J, et al: Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the clinical index of stable febrile neutropenia in a prospective cohort of patients from the FINITE study. *J Clin Oncol* 33: 465, 2015. [PMID: 25559804]
32. Adelberg DE, Bishop MR: Emergencies related to cancer chemotherapy and hematopoietic stem cell transplantation. *Emerg Med Clin North Am* 27: 311, 2009. [PMID: 19447314]
33. Kern WV, Marchetti O, Drgona L, et al: Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy—EORTC infectious diseases group trial XV. *J Clin Oncol* 31: 1149, 2013. [PMID: 23358983]
34. Kwaan HC, Bongu A: The hyperviscosity syndromes. *Semin Thromb Hemost* 25: 199, 1999. [PMID: 10357087]
35. Adams BD, Baker R, Lopez JA, Spencer S: Myeloproliferative disorders and the hyperviscosity syndrome. *Hematol Oncol Clin North Am* 24: 585, 2010. [PMID: 20488356]
36. Stone MJ, Bogen SA: Evidence-based focused review of management of hyperviscosity syndrome. *Blood* 119: 2205, 2012. [PMID: 22147890]
37. Ornstein DL, Zacharski LR: Cancer, thrombosis, and anticoagulants. *Curr Opin Pulm Med* 6: 301, 2000. [PMID: 10912637]
38. Streiff MB: Diagnosis and initial treatment of venous thromboembolism in patients with cancer. *J Clin Oncol* 27: 4889, 2009. [PMID: 19738109]
39. DeLoughery TG: Venous thrombotic emergencies. *Hematol Oncol Clin North Am* 24: 487, 2010. [PMID: 20488349]
40. Akl EA, Kahale L, Neumann I, et al: Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. *Cochrane Database Syst Rev* 6: CD006649, 2014. [PMID: 24945634]
41. Lyman GH, Bohlke K, Khorana AA, et al: Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. *J Clin Oncol* 33: 654, 2015. [PMID: 25605844]
42. Akl EA, Kahale L, Barba M, et al: Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. *Cochrane Database Syst Rev* 7: CD006650, 2014. [PMID: 25004410]
43. Basch E, Prestreud AA, Hesketh PJ, et al: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 29: 4189, 2011. [Erratum in: *J Clin Oncol* 32: 2117, 2014. Dosage error in article text.] [PMID: 21947834]
44. Jordan K, Gralla R, Jahn F, Molassiotis A: International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. *Eur J Pharmacol* 722: 197, 2014. [PMID: 24157984]
45. Janelsins MC, Tejani MA, Kamen C, Peoples AR, Mustian KM, Morrow GR: Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. *Expert Opin Pharmacother* 14: 757, 2013. [PMID: 23496347]
46. Livshits Z, Rao RB, Smith SW: An approach to chemotherapy-associated toxicity. *Emerg Med Clin North Am* 32: 167, 2014. [PMID: 24275174]
47. Young JS, Simmons JW: Chemotherapeutic medications and their emergent complications. *Emerg Med Clin North Am* 32: 563, 2014. [PMID: 25060250]
48. de Wit M, Ortner P, Lipp HP, et al: Management of cytotoxic extravasation: ASORS expert opinion for diagnosis, prevention and treatment. *Onkologie* 36: 127, 2013. [PMID: 23486002]
49. Langer SW: Dexrazoxane for the treatment of chemotherapy-related side effects. *Cancer Manag Res* 6: 357, 2014. [PMID: 25246808]

USEFUL WEB RESOURCES

- American Association for Cancer Research—<http://www.aacr.org>
- American Cancer Society Information for Health Care Professionals—<http://www.cancer.org/healthy/informationforhealthcareprofessionals/index>
- American Society of Clinical Oncology—<http://www.asco.org>
- Multinational Association for Supportive Care in Cancer—<http://www.mascc.org/>